Compare Comcast Corporation (CMCSA) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Neurocrine Biosciences Inc — how do they compare? Comcast Corporation trades at $25.59 (market cap $89.43B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Comcast Corporation is far larger — about 5.3× Neurocrine Biosciences Inc's market cap, and Comcast Corporation pays a 5.24% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CMCSA | NBIX | |
|---|---|---|
Market Cap | $89.43B | $16.76B |
Sector | Media | Health |
52-Week High | $32.50 | $185.50 |
52-Week Low | $21.92 | $123.10 |
Enterprise Value | $172.15B | $16.78B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.36, up 0.75% today, with strong technical momentum showing bullish moving averages and support at $25. The company demonstrates robust fundamentals with a low P/E of 8.13 and consistent earnings beats, including Q2 2026 EPS of $1.04 versus $0.97 expected. Recent expansion announcements in Florida and New Hampshire highlight ongoing growth initiatives.
CMCSA presents compelling value with discounted valuation multiples and a 55.74% analyst buy rating. Key opportunities include wireless growth and Peacock profitability, while risks involve competitive pressures and the planned NBCUniversal spinoff. The consensus price target of $27.78 suggests 9.5% upside potential from current levels.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
